華寶國際(00336.HK)附屬索賠逾3.3億人幣
華寶國際(00336.HK)公布,有關非全資附屬華寶股份(300741.SZ)收購上海奕方部分股權一事,依據股份轉讓協定的約定終止該協議權利義務關係,並以錢戎及黃錦榮為被申請人,向上海國際仲裁中心申請仲裁,請求裁決錢戎和黃錦榮向華寶股份賠償違約金、預期利益損失、律師費合計3.32億元人民幣(下同)等,同時申請財產保全,並於8月9日(昨日)收到受理通知。
公司指,錢戎、黃錦榮仍然未履行股份轉讓協議下第二期增資款,合計709.57萬元繳納義務,且在收到華寶股份書面通知日後15日內仍未改正,同時考慮到上海奕方在業績承諾期內持續虧損,因此依據股份轉讓協定的約定終止該份協議的權利義務關係。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.